Institution
Monash Institute of Medical Research
Healthcare•Clayton, Victoria, Australia•
About: Monash Institute of Medical Research is a healthcare organization based out in Clayton, Victoria, Australia. It is known for research contribution in the topics: Stem cell & Embryonic stem cell. The organization has 749 authors who have published 1162 publications receiving 66110 citations.
Topics: Stem cell, Embryonic stem cell, Cellular differentiation, Polysomnography, Innate immune system
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This Review discusses four main effector pathways of the IFN-mediated antiviral response: the Mx GTPase pathway, the 2′,5′-oligoadenylate-synthetase-directed ribonuclease L pathways, the protein kinase R pathway and the ISG15 ubiquitin-like pathway.
Abstract: Since the discovery of interferons (IFNs), considerable progress has been made in describing the nature of the cytokines themselves, the signalling components that direct the cell response and their antiviral activities. Gene targeting studies have distinguished four main effector pathways of the IFN-mediated antiviral response: the Mx GTPase pathway, the 2',5'-oligoadenylate-synthetase-directed ribonuclease L pathway, the protein kinase R pathway and the ISG15 ubiquitin-like pathway. As discussed in this Review, these effector pathways individually block viral transcription, degrade viral RNA, inhibit translation and modify protein function to control all steps of viral replication. Ongoing research continues to expose additional activities for these effector proteins and has revealed unanticipated functions of the antiviral response.
1,927 citations
••
TL;DR: A model in which one of the crucial elements for NLRP3 activation is the generation of reactive oxygen species (ROS) is suggested.
Abstract: This Opinion article discusses the evidence for and the limitations of the three main models of inflammasome activation. The authors propose that the production of reactive oxygen species might be a common factor downstream of many types of inflammasome activator. The NLR family, pyrin domain-containing 3 (NLRP3) inflammasome is a multiprotein complex that activates caspase 1, leading to the processing and secretion of the pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18. The NLRP3 inflammasome is activated by a wide range of danger signals that derive not only from microorganisms but also from metabolic dysregulation. It is unclear how these highly varied stress signals can be detected by a single inflammasome. In this Opinion article, we review the different signalling pathways that have been proposed to engage the NLRP3 inflammasome and suggest a model in which one of the crucial elements for NLRP3 activation is the generation of reactive oxygen species (ROS).
1,492 citations
••
29 Jun 2017
TL;DR: Vitamin B12 deficiency causes reversible megaloblastic anemia, demyelinating disease, or both; current assays have insufficient sensitivity and specificity; methylmalonic acid levels are useful to confirm diagnosis.
Abstract: Vitamin B12 deficiency causes reversible megaloblastic anemia, demyelinating disease, or both. Current assays have insufficient sensitivity and specificity; methylmalonic acid levels are useful to confirm diagnosis. Parenteral or high-dose oral vitamin B12 is effective therapy.
1,066 citations
••
TL;DR: Recent advances in the knowledge of EMT as it occurs in breast development and carcinoma and prostate cancer progression are detailed, and the role that MET plays in cancer metastasis is highlighted.
Abstract: Like a set of bookends, cellular, molecular, and genetic changes of the beginnings of life mirror those of one of the most common cause of death--metastatic cancer. Epithelial to mesenchymal transition (EMT) is an important change in cell phenotype which allows the escape of epithelial cells from the structural constraints imposed by tissue architecture, and was first recognized by Elizabeth Hay in the early to mid 1980's to be a central process in early embryonic morphogenesis. Reversals of these changes, termed mesenchymal to epithelial transitions (METs), also occur and are important in tissue construction in normal development. Over the last decade, evidence has mounted for EMT as the means through which solid tissue epithelial cancers invade and metastasize. However, demonstrating this potentially rapid and transient process in vivo has proven difficult and data connecting the relevance of this process to tumor progression is still somewhat limited and controversial. Evidence for an important role of MET in the development of clinically overt metastases is starting to accumulate, and model systems have been developed. This review details recent advances in the knowledge of EMT as it occurs in breast development and carcinoma and prostate cancer progression, and highlights the role that MET plays in cancer metastasis. Finally, perspectives from a clinical and translational viewpoint are discussed.
1,015 citations
01 Nov 2007
TL;DR: The mesenchymal to epithelial transition (EMT) as mentioned in this paper is an important change in cell phenotype which allows the escape of epithelial cells from the structural constraints imposed by tissue architecture, and was recognized by Elizabeth Hay in the early to mid 1980's to be a central process in early embryonic morphogenesis.
Abstract: Like a set of bookends, cellular, molecular, and genetic changes of the beginnings of life mirror those of one of the most common cause of death—metastatic cancer. Epithelial to mesenchymal transition (EMT) is an important change in cell phenotype which allows the escape of epithelial cells from the structural constraints imposed by tissue architecture, and was first recognized by Elizabeth Hay in the early to mid 1980's to be a central process in early embryonic morphogenesis. Reversals of these changes, termed mesenchymal to epithelial transitions (METs), also occur and are important in tissue construction in normal development. Over the last decade, evidence has mounted for EMT as the means through which solid tissue epithelial cancers invade and metastasize. However, demonstrating this potentially rapid and transient process in vivo has proven difficult and data connecting the relevance of this process to tumor progression is still somewhat limited and controversial. Evidence for an important role of MET in the development of clinically overt metastases is starting to accumulate, and model systems have been developed. This review details recent advances in the knowledge of EMT as it occurs in breast development and carcinoma and prostate cancer progression, and highlights the role that MET plays in cancer metastasis. Finally, perspectives from a clinical and translational viewpoint are discussed
940 citations
Authors
Showing all 750 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jun Liu | 100 | 1165 | 73692 |
Bryan R.G. Williams | 97 | 381 | 40306 |
Atul Malhotra | 97 | 794 | 40203 |
Robert G. Cumming | 97 | 515 | 38309 |
Gerald R. Cunha | 95 | 365 | 29563 |
Alan O Trounson | 92 | 541 | 33785 |
David J. Handelsman | 90 | 612 | 27518 |
Di Wu | 87 | 965 | 48697 |
John A. Hamilton | 79 | 490 | 26662 |
Fabienne Mackay | 75 | 188 | 26019 |
Christopher J.H. Porter | 75 | 286 | 20094 |
Gary A. Wittert | 68 | 462 | 16759 |
D. M. De Kretser | 68 | 275 | 15098 |
Judith A. Clements | 68 | 320 | 17649 |
Peter Rogers | 67 | 408 | 14442 |